

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

## Complete if Known

Sheet 1 of 1

Application Number 10/625,866  
Filing Date July 22, 2003  
First Named Inventor BROWN, Dennis M.  
Art Unit 1614  
Examiner Name HENLEY III, Raymond J.  
Attorney Docket Number 067716-5012-US

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign patent Document Country Code <sup>2</sup> Number <sup>2</sup> Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
/R.H./	B1	WO 02/32904	04-25-2002	Oncopharm Corp		
/R.H./	B2	WO 01/68098	09-20-2001	Chemgenex Therapeutics, Inc.		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/R.H./	C1	BAGULEY, Bruce C., et al., "Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor $\alpha$ on colon 38 tumours in mice," Eur. J. Cancer Clin Oncol., v. 25, n. 2, p. 263-269, 1989.
	C2	FOUNTZILAS, G., et al., "The inhibitory effects of teniposide and homoharringtonine on the growth of pancreatic carcinoma cells <i>in vitro</i> ," Anticancer Research, v. 8, n. 3, May-June 1988.
	C3	TAKANO I. et al. Ester-type cephalotaxus alkaloids from cephalotaxus harringtonia var. drupacea," Phytochemistry, Pergamon Press, GB, vol. 44, no. 4, February 1997, pages 735-738.
	C4	TEBBI, Cameron K., et al., "Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporine A and dipyrindamole," J. of Cellular Physiology, v. 148 p. 464-471, 1991.
	C5	WILKOFF, Lee J., et al., "Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine," Cancer Chemother Pharmacol, v. 33, p. 149-153, 1993.
/R.H./	C6	ZHANG et al. "Inhibitory effects of homoharringtonine and hydroxycamptothecin in combination with other agents on cancer cell growth," Asia pacific Journal of Pharmacology, Singapore University Press, SG., vol. 7, 1992, pages 191-195.

DB2/2057947.1

Examiner Signature	/Raymond Henley III/	Date Considered	08/07/2009
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.